Scholarlink

Background <p>Methionine aminopeptidase (MetAP2) is a multifunctional protein that plays a significant role in regulating protein synthesis and post-translational modifications. Although its involvement in the development of various cancers is well-documented, its precise function in head and neck squamous cell carcinoma (HNSCC) remains unclear. This study aimed to investigate the specific role of MetAP2 in HNSCC and its potential as a biomarker and therapeutic target.</p> Methods <p>We utilized data from The Cancer Genome Atlas (TCGA)-HNSCC dataset to analyze MetAP2 expression levels in HNSCC tissues. To further validate these findings, MetAP2 mRNA expression was confirmed through RT-qPCR analysis on oral squamous cell carcinoma (OSCC) samples, the most common subtype of HNSCC. In addition, the relationship between MetAP2 expression and clinicopathological features, as well as patient prognosis, was examined using the TCGA-HNSCC dataset. To explore the functional role of MetAP2 in HNSCC pathogenesis, gene-gene interactions and associated pathways were analyzed using GeneMANIA and Metascape tools.</p> Results <p>The results showed that HNSCC tissues exhibit significantly higher levels of MetAP2 compared to non-tumor tissues. Abnormal MetAP2 expression was found to be strongly associated with key clinicopathological factors, such as tumor grade and stage. Furthermore, high MetAP2 expression was negatively correlated with immune characteristics, which had a detrimental impact on overall survival rates. In silico analysis revealed that MetAP2 interacts with several oncogenes, including MetAP1, GNAT1, and RFC5, and is involved in pathways related to ribosome biogenesis.</p> Conclusion <p>MetAP2 appears to be a promising biomarker and therapeutic target in HNSCC. Further research is warranted to explore novel therapeutic strategies and to identify prognostic biomarkers for better HNSCC management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic and Clinical Significance of MetAP2 Overexpression in Head and Neck Cancer

  • 期刊论文

  • 发表日期：

    2025年6月18日

查看全文
  • Barat Kumar Mohan Kumar,
  • Chandra Pandi,
  • Vijayashree Priyadharsini Jayaseelan,
  • Paramasivam Arumugam

摘要

Background

Methionine aminopeptidase (MetAP2) is a multifunctional protein that plays a significant role in regulating protein synthesis and post-translational modifications. Although its involvement in the development of various cancers is well-documented, its precise function in head and neck squamous cell carcinoma (HNSCC) remains unclear. This study aimed to investigate the specific role of MetAP2 in HNSCC and its potential as a biomarker and therapeutic target.

Methods

We utilized data from The Cancer Genome Atlas (TCGA)-HNSCC dataset to analyze MetAP2 expression levels in HNSCC tissues. To further validate these findings, MetAP2 mRNA expression was confirmed through RT-qPCR analysis on oral squamous cell carcinoma (OSCC) samples, the most common subtype of HNSCC. In addition, the relationship between MetAP2 expression and clinicopathological features, as well as patient prognosis, was examined using the TCGA-HNSCC dataset. To explore the functional role of MetAP2 in HNSCC pathogenesis, gene-gene interactions and associated pathways were analyzed using GeneMANIA and Metascape tools.

Results

The results showed that HNSCC tissues exhibit significantly higher levels of MetAP2 compared to non-tumor tissues. Abnormal MetAP2 expression was found to be strongly associated with key clinicopathological factors, such as tumor grade and stage. Furthermore, high MetAP2 expression was negatively correlated with immune characteristics, which had a detrimental impact on overall survival rates. In silico analysis revealed that MetAP2 interacts with several oncogenes, including MetAP1, GNAT1, and RFC5, and is involved in pathways related to ribosome biogenesis.

Conclusion

MetAP2 appears to be a promising biomarker and therapeutic target in HNSCC. Further research is warranted to explore novel therapeutic strategies and to identify prognostic biomarkers for better HNSCC management.